Equities research analysts expect BIOLINERX LTD/S (NASDAQ:BLRX) to report ($0.05) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for BIOLINERX LTD/S’s earnings. BIOLINERX LTD/S reported earnings per share of ($0.06) during the same quarter last year, which suggests a positive year over year growth rate of 16.7%. The business is scheduled to issue its next quarterly earnings results on Tuesday, May 28th.
According to Zacks, analysts expect that BIOLINERX LTD/S will report full year earnings of ($0.20) per share for the current financial year, with EPS estimates ranging from ($0.21) to ($0.18). For the next year, analysts expect that the company will post earnings of ($0.21) per share, with EPS estimates ranging from ($0.24) to ($0.17). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for BIOLINERX LTD/S.
BIOLINERX LTD/S (NASDAQ:BLRX) last announced its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.04.
Shares of BLRX stock traded down $0.01 during mid-day trading on Tuesday, reaching $0.37. 661,840 shares of the stock traded hands, compared to its average volume of 1,247,476. BIOLINERX LTD/S has a 1-year low of $0.36 and a 1-year high of $1.84. The firm has a market capitalization of $40.42 million, a price-to-earnings ratio of -1.76 and a beta of 1.70. The company has a current ratio of 4.74, a quick ratio of 4.74 and a debt-to-equity ratio of 0.19.
Several institutional investors have recently bought and sold shares of the stock. Deutsche Bank AG acquired a new position in shares of BIOLINERX LTD/S in the fourth quarter worth approximately $26,000. Two Sigma Securities LLC acquired a new position in shares of BIOLINERX LTD/S in the fourth quarter worth approximately $25,000. Menta Capital LLC acquired a new position in shares of BIOLINERX LTD/S in the fourth quarter worth approximately $33,000. Finally, ETF Managers Group LLC lifted its stake in shares of BIOLINERX LTD/S by 79.4% in the fourth quarter. ETF Managers Group LLC now owns 375,909 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 166,386 shares during the period. 33.79% of the stock is currently owned by institutional investors.
About BIOLINERX LTD/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Featured Article: What Does a Sell-Side Analyst Rating Mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.